The effect of the tachykinin NK2 receptor antagonist MEN11420 (nepadutant) on neurokinin A-induced bronchoconstriction in asthmatics
Authors:
Open Access
- 30 October 2009
- journal article
- research article
- Published by SAGE Publications in Therapeutic Advances in Respiratory Disease
- Vol. 3 (5) , 219-226
Abstract
Objective: We previously reported that the nonpeptide tachykinin NK2 receptor antagonist SR48968 (saredutant) significantly inhibits neurokinin A-induced bronchoconstriction in patients with asthma. MEN11420 (nepadutant) is a bicyclic peptide tachykinin NK2 receptor antagonist. The aim of the trial was to examine the effect of nepadutant on neurokinin A-induced bronchoconstriction in man. Methods: 12 patients with stable, mild to moderate asthma participated in a double-blind, placebo-controlled crossover trial and received, with intervals of 1 week, MEN11420 2 mg, MEN11420 8 mg and placebo (i.v.). Increasing concentrations of NKA (10-9 to 10-6 moles/ml) were inhaled immediately after (d1) and 24 hours after (d2) administration of treatment. Results: On d1 both MEN11420 2 and 8 mg shifted the dose response curve for neurokinin A to the right (log PC20 FEV1 neurokinin A [moles/ml]; mean± SEM -6.38±0.26 after 2 mg, -6.11±0.23 after 8 mg, versus -6.95±0.27 after placebo]. On d2 MEN11420 had no effect on neurokinin A-induced bronchoconstriction. Conclusion: In conclusion, the tachykinin NK2 receptor antagonist nepadutant significantly inhibits bronchoconstriction induced by neurokinin A in patients with asthma.Keywords
This publication has 18 references indexed in Scilit:
- Multifaceted Approach to Determine the Antagonist Molecular Mechanism and Interaction of Ibodutant ([1-(2-Phenyl-1R-{[1-(tetrahydropyran-4-ylmethyl)-piperidin-4-ylmethyl]-carbamoyl}-ethylcarbamoyl)-cyclopentyl]-amide) at the Human Tachykinin NK2 ReceptorThe Journal of Pharmacology and Experimental Therapeutics, 2009
- The triple neurokinin-receptor antagonist CS-003 inhibits neurokinin A-induced bronchoconstriction in patients with asthmaPulmonary Pharmacology & Therapeutics, 2006
- MEN15596, a novel nonpeptide tachykinin NK2 receptor antagonistEuropean Journal of Pharmacology, 2006
- A novel tachykinin NK2 receptor antagonist prevents motility‐stimulating effects of neurokinin A in small intestineBritish Journal of Pharmacology, 2001
- NK1 Receptor Stimulation Causes Contraction and Inositol Phosphate Increase in Medium-size Human Isolated BronchiAmerican Journal of Respiratory and Critical Care Medicine, 2001
- Pro-inflammatory effects of substance P: new perspectives for the treatment of airway diseases?Trends in Pharmacological Sciences, 2000
- Interleukin-1β-induced hyperresponsiveness to [Sar9,Met(O2)11]substance P in isolated human bronchiEuropean Journal of Pharmacology, 1999
- MEN 11420 (Nepadutant), a novel glycosylated bicyclic peptide tachykinin NK2 receptor antagonistBritish Journal of Pharmacology, 1998
- Effect of inhaled substance P and neurokinin A on the airways of normal and asthmatic subjects.Thorax, 1987
- Bronchial reactivity to inhaled histamine: a method and clinical surveyClinical & Experimental Allergy, 1977